Long W, Corbet A, Allen A, McMillan D, Boros S, Vaughan R, Gerdes J, Houle L, Edwards K, Schiff D
Department of Pediatrics, University of North Carolina, Chapel Hill.
J Pediatr. 1992 Feb;120(2 Pt 2):S45-8. doi: 10.1016/s0022-3476(05)81233-8.
In an across study analysis of five multicenter, placebo-controlled trials of the synthetic surfactant, Exosurf Neonatal, involving infants with birth weights 700 gm or greater the incidence of clinical pulmonary hemorrhage was 1.9% in treated infants and 1.0% in control infants. To determine whether this apparent increase in pulmonary hemorrhage was the result of a bleeding diathesis, we retrospectively reviewed charts for 39 of 41 infants with clinical pulmonary hemorrhage. The incidence of nonpulmonary bleeding was the same in control- and surfactant-treated infants. Platelet counts, hematocrit values, and the number of transfusions with platelets or red blood cells did not differ between the two groups. There was no evidence that surfactant treatment was specifically associated with a generalized bleeding diathesis.
在一项对合成表面活性剂Exosurf Neonatal进行的五项多中心、安慰剂对照试验的综合研究分析中，涉及出生体重700克或以上的婴儿，治疗组婴儿临床肺出血的发生率为1.9%，对照组婴儿为1.0%。为了确定这种明显的肺出血增加是否是出血素质的结果，我们回顾性地查阅了41例临床肺出血婴儿中39例的病历。对照组和表面活性剂治疗组婴儿的非肺出血发生率相同。两组之间的血小板计数、血细胞比容值以及血小板或红细胞的输血次数没有差异。没有证据表明表面活性剂治疗与全身性出血素质有特定关联。
